Loading…

A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization

Glycans on the human immunodeficiency virus (HIV) envelope glycoprotein (Env) play an important role in viral infection and evasion of neutralization by antibodies. In this study, all 25 potential N-linked glycosylation sites (PNGS) on the HIV-1 CRF07_BC Env, FE, were mutated individually to study t...

Full description

Saved in:
Bibliographic Details
Published in:Retrovirology 2013-02, Vol.10 (1), p.14-14, Article 14
Main Authors: Wang, Wenbo, Nie, Jianhui, Prochnow, Courtney, Truong, Carolyn, Jia, Zheng, Wang, Suting, Chen, Xiaojiang S, Wang, Youchun
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c587t-ea331278f69c9ae45c9ac33d410658748c74031f81338d955f1cde4da8b958193
cites cdi_FETCH-LOGICAL-c587t-ea331278f69c9ae45c9ac33d410658748c74031f81338d955f1cde4da8b958193
container_end_page 14
container_issue 1
container_start_page 14
container_title Retrovirology
container_volume 10
creator Wang, Wenbo
Nie, Jianhui
Prochnow, Courtney
Truong, Carolyn
Jia, Zheng
Wang, Suting
Chen, Xiaojiang S
Wang, Youchun
description Glycans on the human immunodeficiency virus (HIV) envelope glycoprotein (Env) play an important role in viral infection and evasion of neutralization by antibodies. In this study, all 25 potential N-linked glycosylation sites (PNGS) on the HIV-1 CRF07_BC Env, FE, were mutated individually to study the effect of their removal on viral infectivity, virion production, and antibody-mediated neutralization. Removal of specific N-glycosylation sites has a significant effect on viral infectivity and antibody-mediated neutralization phenotype. Six of these glycosylation mutants located on the V1/V2 and C1/C2 domains lost infectivity. PNGS mutations located on V4/C4/V5 (except N392 on V4), were shown to increase viral infectivity. Furthermore, FE is much more dependent on specific glycans than clade B Env YU-2. On neutralization effect, PNGS mutations at N197 (C2), N301 (V3), N442 (C4) and N625 (gp41) rendered the virus more susceptible to neutralization by the monoclonal antibodies (MAbs) that recognize the CD4 binding site or gp41. Generally, mutations on V4/V5 loops, C2/C3/C4 regions and gp41 reduced the neutralization sensitivity to PG16. However, mutation of N289 (C2) made the virus more sensitive to both PG9 and PG16. Furthermore, we showed that mutations at N142 (V1), N355 (C3) and N463 (V5) conferred resistance to neutralization by anti-gp41 MAbs. We used the available structural information of HIV Env and homology modeling to provide a structural basis for the observed biological effects of these mutations. This report provides the first systematic experimental account of the biological role of the entire PNGS on an HIV-1 Env, which should provide valuable insights for understanding the function of Env in HIV infection cycle and for developing future anti-HIV strategies.
doi_str_mv 10.1186/1742-4690-10-14
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3648360</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534690417</galeid><sourcerecordid>A534690417</sourcerecordid><originalsourceid>FETCH-LOGICAL-c587t-ea331278f69c9ae45c9ac33d410658748c74031f81338d955f1cde4da8b958193</originalsourceid><addsrcrecordid>eNqNks9rFTEQx4MotlbP3iTgxcu2ySbZTS7Co6gtFL2o15CXzL6m7CbPTfbBFvzfzb7WZyseJD-Z-cyXyWQQek3JKaWyOaMtryveKFLRMvkTdHywPH1wP0IvUrohhFFJ5HN0VDMmeS34Mfq5wmlOGQaTvcUpT27GscP5GvDnatPPNqa5L74YcPIZ0uK8uPxeUQxhB33cAt6OMYMPuCA-dGCz3_k8YxNcWdmvo5urAZw3GRwOMOXR9P52r_kSPetMn-DV_XmCvn388PX8orr68unyfHVVWSHbXIFhjNat7BpllQEuym4Zc5ySpgBc2paXt3WSlnc5JURHrQPujFwrIaliJ-j9ne52WpdULIQlCb0d_WDGWUfj9WNP8Nd6E3eaNVyyhhSBd_cCY_wxQcp68MlC35sAcUqaMlHXSjS0-Q-Uq5ZwRRfVt3-hN3EaQ6lEodqWCylp-4famB50KXEsKdpFVK8EW76X76nTf1BlOBi8jQE6X-yPAs7uAuwYUxqhO5SDEr00l17aRy_43sJLxJuHVTzwv7uJ_QLz2slY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1377458817</pqid></control><display><type>article</type><title>A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization</title><source>NCBI_PubMed Central(免费)</source><source>Publicly Available Content Database</source><creator>Wang, Wenbo ; Nie, Jianhui ; Prochnow, Courtney ; Truong, Carolyn ; Jia, Zheng ; Wang, Suting ; Chen, Xiaojiang S ; Wang, Youchun</creator><creatorcontrib>Wang, Wenbo ; Nie, Jianhui ; Prochnow, Courtney ; Truong, Carolyn ; Jia, Zheng ; Wang, Suting ; Chen, Xiaojiang S ; Wang, Youchun</creatorcontrib><description>Glycans on the human immunodeficiency virus (HIV) envelope glycoprotein (Env) play an important role in viral infection and evasion of neutralization by antibodies. In this study, all 25 potential N-linked glycosylation sites (PNGS) on the HIV-1 CRF07_BC Env, FE, were mutated individually to study the effect of their removal on viral infectivity, virion production, and antibody-mediated neutralization. Removal of specific N-glycosylation sites has a significant effect on viral infectivity and antibody-mediated neutralization phenotype. Six of these glycosylation mutants located on the V1/V2 and C1/C2 domains lost infectivity. PNGS mutations located on V4/C4/V5 (except N392 on V4), were shown to increase viral infectivity. Furthermore, FE is much more dependent on specific glycans than clade B Env YU-2. On neutralization effect, PNGS mutations at N197 (C2), N301 (V3), N442 (C4) and N625 (gp41) rendered the virus more susceptible to neutralization by the monoclonal antibodies (MAbs) that recognize the CD4 binding site or gp41. Generally, mutations on V4/V5 loops, C2/C3/C4 regions and gp41 reduced the neutralization sensitivity to PG16. However, mutation of N289 (C2) made the virus more sensitive to both PG9 and PG16. Furthermore, we showed that mutations at N142 (V1), N355 (C3) and N463 (V5) conferred resistance to neutralization by anti-gp41 MAbs. We used the available structural information of HIV Env and homology modeling to provide a structural basis for the observed biological effects of these mutations. This report provides the first systematic experimental account of the biological role of the entire PNGS on an HIV-1 Env, which should provide valuable insights for understanding the function of Env in HIV infection cycle and for developing future anti-HIV strategies.</description><identifier>ISSN: 1742-4690</identifier><identifier>EISSN: 1742-4690</identifier><identifier>DOI: 10.1186/1742-4690-10-14</identifier><identifier>PMID: 23384254</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Analysis ; Antibodies, Neutralizing - immunology ; env Gene Products, Human Immunodeficiency Virus - chemistry ; env Gene Products, Human Immunodeficiency Virus - genetics ; env Gene Products, Human Immunodeficiency Virus - immunology ; Experiments ; Glycosylation ; Health aspects ; HIV (Viruses) ; HIV Antibodies - immunology ; HIV infection ; HIV-1 - chemistry ; HIV-1 - genetics ; HIV-1 - immunology ; HIV-1 - physiology ; Human immunodeficiency virus ; Human immunodeficiency virus 1 ; Humans ; Infection ; Monoclonal antibodies ; Mutation ; Neutralization Tests ; Polysaccharides ; Proteins ; Virus diseases ; Virus Replication</subject><ispartof>Retrovirology, 2013-02, Vol.10 (1), p.14-14, Article 14</ispartof><rights>COPYRIGHT 2013 BioMed Central Ltd.</rights><rights>2013 Wang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2013 Wang et al; licensee BioMed Central Ltd. 2013 Wang et al; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c587t-ea331278f69c9ae45c9ac33d410658748c74031f81338d955f1cde4da8b958193</citedby><cites>FETCH-LOGICAL-c587t-ea331278f69c9ae45c9ac33d410658748c74031f81338d955f1cde4da8b958193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3648360/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1377458817?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23384254$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Wenbo</creatorcontrib><creatorcontrib>Nie, Jianhui</creatorcontrib><creatorcontrib>Prochnow, Courtney</creatorcontrib><creatorcontrib>Truong, Carolyn</creatorcontrib><creatorcontrib>Jia, Zheng</creatorcontrib><creatorcontrib>Wang, Suting</creatorcontrib><creatorcontrib>Chen, Xiaojiang S</creatorcontrib><creatorcontrib>Wang, Youchun</creatorcontrib><title>A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization</title><title>Retrovirology</title><addtitle>Retrovirology</addtitle><description>Glycans on the human immunodeficiency virus (HIV) envelope glycoprotein (Env) play an important role in viral infection and evasion of neutralization by antibodies. In this study, all 25 potential N-linked glycosylation sites (PNGS) on the HIV-1 CRF07_BC Env, FE, were mutated individually to study the effect of their removal on viral infectivity, virion production, and antibody-mediated neutralization. Removal of specific N-glycosylation sites has a significant effect on viral infectivity and antibody-mediated neutralization phenotype. Six of these glycosylation mutants located on the V1/V2 and C1/C2 domains lost infectivity. PNGS mutations located on V4/C4/V5 (except N392 on V4), were shown to increase viral infectivity. Furthermore, FE is much more dependent on specific glycans than clade B Env YU-2. On neutralization effect, PNGS mutations at N197 (C2), N301 (V3), N442 (C4) and N625 (gp41) rendered the virus more susceptible to neutralization by the monoclonal antibodies (MAbs) that recognize the CD4 binding site or gp41. Generally, mutations on V4/V5 loops, C2/C3/C4 regions and gp41 reduced the neutralization sensitivity to PG16. However, mutation of N289 (C2) made the virus more sensitive to both PG9 and PG16. Furthermore, we showed that mutations at N142 (V1), N355 (C3) and N463 (V5) conferred resistance to neutralization by anti-gp41 MAbs. We used the available structural information of HIV Env and homology modeling to provide a structural basis for the observed biological effects of these mutations. This report provides the first systematic experimental account of the biological role of the entire PNGS on an HIV-1 Env, which should provide valuable insights for understanding the function of Env in HIV infection cycle and for developing future anti-HIV strategies.</description><subject>Analysis</subject><subject>Antibodies, Neutralizing - immunology</subject><subject>env Gene Products, Human Immunodeficiency Virus - chemistry</subject><subject>env Gene Products, Human Immunodeficiency Virus - genetics</subject><subject>env Gene Products, Human Immunodeficiency Virus - immunology</subject><subject>Experiments</subject><subject>Glycosylation</subject><subject>Health aspects</subject><subject>HIV (Viruses)</subject><subject>HIV Antibodies - immunology</subject><subject>HIV infection</subject><subject>HIV-1 - chemistry</subject><subject>HIV-1 - genetics</subject><subject>HIV-1 - immunology</subject><subject>HIV-1 - physiology</subject><subject>Human immunodeficiency virus</subject><subject>Human immunodeficiency virus 1</subject><subject>Humans</subject><subject>Infection</subject><subject>Monoclonal antibodies</subject><subject>Mutation</subject><subject>Neutralization Tests</subject><subject>Polysaccharides</subject><subject>Proteins</subject><subject>Virus diseases</subject><subject>Virus Replication</subject><issn>1742-4690</issn><issn>1742-4690</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqNks9rFTEQx4MotlbP3iTgxcu2ySbZTS7Co6gtFL2o15CXzL6m7CbPTfbBFvzfzb7WZyseJD-Z-cyXyWQQek3JKaWyOaMtryveKFLRMvkTdHywPH1wP0IvUrohhFFJ5HN0VDMmeS34Mfq5wmlOGQaTvcUpT27GscP5GvDnatPPNqa5L74YcPIZ0uK8uPxeUQxhB33cAt6OMYMPuCA-dGCz3_k8YxNcWdmvo5urAZw3GRwOMOXR9P52r_kSPetMn-DV_XmCvn388PX8orr68unyfHVVWSHbXIFhjNat7BpllQEuym4Zc5ySpgBc2paXt3WSlnc5JURHrQPujFwrIaliJ-j9ne52WpdULIQlCb0d_WDGWUfj9WNP8Nd6E3eaNVyyhhSBd_cCY_wxQcp68MlC35sAcUqaMlHXSjS0-Q-Uq5ZwRRfVt3-hN3EaQ6lEodqWCylp-4famB50KXEsKdpFVK8EW76X76nTf1BlOBi8jQE6X-yPAs7uAuwYUxqhO5SDEr00l17aRy_43sJLxJuHVTzwv7uJ_QLz2slY</recordid><startdate>20130206</startdate><enddate>20130206</enddate><creator>Wang, Wenbo</creator><creator>Nie, Jianhui</creator><creator>Prochnow, Courtney</creator><creator>Truong, Carolyn</creator><creator>Jia, Zheng</creator><creator>Wang, Suting</creator><creator>Chen, Xiaojiang S</creator><creator>Wang, Youchun</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130206</creationdate><title>A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization</title><author>Wang, Wenbo ; Nie, Jianhui ; Prochnow, Courtney ; Truong, Carolyn ; Jia, Zheng ; Wang, Suting ; Chen, Xiaojiang S ; Wang, Youchun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c587t-ea331278f69c9ae45c9ac33d410658748c74031f81338d955f1cde4da8b958193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Analysis</topic><topic>Antibodies, Neutralizing - immunology</topic><topic>env Gene Products, Human Immunodeficiency Virus - chemistry</topic><topic>env Gene Products, Human Immunodeficiency Virus - genetics</topic><topic>env Gene Products, Human Immunodeficiency Virus - immunology</topic><topic>Experiments</topic><topic>Glycosylation</topic><topic>Health aspects</topic><topic>HIV (Viruses)</topic><topic>HIV Antibodies - immunology</topic><topic>HIV infection</topic><topic>HIV-1 - chemistry</topic><topic>HIV-1 - genetics</topic><topic>HIV-1 - immunology</topic><topic>HIV-1 - physiology</topic><topic>Human immunodeficiency virus</topic><topic>Human immunodeficiency virus 1</topic><topic>Humans</topic><topic>Infection</topic><topic>Monoclonal antibodies</topic><topic>Mutation</topic><topic>Neutralization Tests</topic><topic>Polysaccharides</topic><topic>Proteins</topic><topic>Virus diseases</topic><topic>Virus Replication</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Wenbo</creatorcontrib><creatorcontrib>Nie, Jianhui</creatorcontrib><creatorcontrib>Prochnow, Courtney</creatorcontrib><creatorcontrib>Truong, Carolyn</creatorcontrib><creatorcontrib>Jia, Zheng</creatorcontrib><creatorcontrib>Wang, Suting</creatorcontrib><creatorcontrib>Chen, Xiaojiang S</creatorcontrib><creatorcontrib>Wang, Youchun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Retrovirology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Wenbo</au><au>Nie, Jianhui</au><au>Prochnow, Courtney</au><au>Truong, Carolyn</au><au>Jia, Zheng</au><au>Wang, Suting</au><au>Chen, Xiaojiang S</au><au>Wang, Youchun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization</atitle><jtitle>Retrovirology</jtitle><addtitle>Retrovirology</addtitle><date>2013-02-06</date><risdate>2013</risdate><volume>10</volume><issue>1</issue><spage>14</spage><epage>14</epage><pages>14-14</pages><artnum>14</artnum><issn>1742-4690</issn><eissn>1742-4690</eissn><abstract>Glycans on the human immunodeficiency virus (HIV) envelope glycoprotein (Env) play an important role in viral infection and evasion of neutralization by antibodies. In this study, all 25 potential N-linked glycosylation sites (PNGS) on the HIV-1 CRF07_BC Env, FE, were mutated individually to study the effect of their removal on viral infectivity, virion production, and antibody-mediated neutralization. Removal of specific N-glycosylation sites has a significant effect on viral infectivity and antibody-mediated neutralization phenotype. Six of these glycosylation mutants located on the V1/V2 and C1/C2 domains lost infectivity. PNGS mutations located on V4/C4/V5 (except N392 on V4), were shown to increase viral infectivity. Furthermore, FE is much more dependent on specific glycans than clade B Env YU-2. On neutralization effect, PNGS mutations at N197 (C2), N301 (V3), N442 (C4) and N625 (gp41) rendered the virus more susceptible to neutralization by the monoclonal antibodies (MAbs) that recognize the CD4 binding site or gp41. Generally, mutations on V4/V5 loops, C2/C3/C4 regions and gp41 reduced the neutralization sensitivity to PG16. However, mutation of N289 (C2) made the virus more sensitive to both PG9 and PG16. Furthermore, we showed that mutations at N142 (V1), N355 (C3) and N463 (V5) conferred resistance to neutralization by anti-gp41 MAbs. We used the available structural information of HIV Env and homology modeling to provide a structural basis for the observed biological effects of these mutations. This report provides the first systematic experimental account of the biological role of the entire PNGS on an HIV-1 Env, which should provide valuable insights for understanding the function of Env in HIV infection cycle and for developing future anti-HIV strategies.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>23384254</pmid><doi>10.1186/1742-4690-10-14</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1742-4690
ispartof Retrovirology, 2013-02, Vol.10 (1), p.14-14, Article 14
issn 1742-4690
1742-4690
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3648360
source NCBI_PubMed Central(免费); Publicly Available Content Database
subjects Analysis
Antibodies, Neutralizing - immunology
env Gene Products, Human Immunodeficiency Virus - chemistry
env Gene Products, Human Immunodeficiency Virus - genetics
env Gene Products, Human Immunodeficiency Virus - immunology
Experiments
Glycosylation
Health aspects
HIV (Viruses)
HIV Antibodies - immunology
HIV infection
HIV-1 - chemistry
HIV-1 - genetics
HIV-1 - immunology
HIV-1 - physiology
Human immunodeficiency virus
Human immunodeficiency virus 1
Humans
Infection
Monoclonal antibodies
Mutation
Neutralization Tests
Polysaccharides
Proteins
Virus diseases
Virus Replication
title A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T08%3A36%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20systematic%20study%20of%20the%20N-glycosylation%20sites%20of%20HIV-1%20envelope%20protein%20on%20infectivity%20and%20antibody-mediated%20neutralization&rft.jtitle=Retrovirology&rft.au=Wang,%20Wenbo&rft.date=2013-02-06&rft.volume=10&rft.issue=1&rft.spage=14&rft.epage=14&rft.pages=14-14&rft.artnum=14&rft.issn=1742-4690&rft.eissn=1742-4690&rft_id=info:doi/10.1186/1742-4690-10-14&rft_dat=%3Cgale_pubme%3EA534690417%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c587t-ea331278f69c9ae45c9ac33d410658748c74031f81338d955f1cde4da8b958193%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1377458817&rft_id=info:pmid/23384254&rft_galeid=A534690417&rfr_iscdi=true